Clinical trials: Multiple Pregnancy
Ovarian Cancer, Relapsed or Refractory
Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
This randomized, double-blind, 2-arm study will evaluate the efficacy and safety of Chiauranib plus weekly paclitaxel versus placebo plus weekly paclitaxel in patients with Platinum-refractory or Platinum-resistant Recurrent…
- Conditions
- Ovarian Cancer, Relapsed or Refractory, Chiauranib, Paclitaxel
- Trial name
- CHIPRO (NCT04921527)
- Testing
- chiauranib, Paclitaxel
- Where
- China
- Volunteers
- 454 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Multiple Sclerosis
Kesimpta Pregnancy and Infant Safety Study Using Real World Data
The study is an observational retrospective cohort study using longitudinal secondary data. Pregnant women with MS are assessed for exposure to Kesimpta and other MS disease modifying drugs (MSDMD) and followed up for adverse…
- Trial name
- NCT06156683
- Testing
- Multiple sclerosis disease modifying drug
- Where
- Switzerland
- Volunteers
- 1,500 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Cancer Recurrent
DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer
The purpose of this trial is to investigate if maintenance DCVAC/OvCa after second-line chemotherapy of carboplatin/gemcitabine or carboplatin/paclitaxel improves efficacy outcomes in women with FIGO stage III and IV epithelial…
- Trial name
- NCT03657966
- Testing
- DCVAC/OvCa, Standard of Care Chemotherapy
- Where
- 8 sites in Czechia
- Volunteers
- 33 people
- Sponsor
- SOTIO a.s.
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Diabetic Nephropathies
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy.
- Trial name
- ARTS-DN (NCT01874431)
- Testing
- Finerenone (BAY94-8862)
- Where
- 147 sites in United States, Australia and 21 more
- Volunteers
- 823 people
- Sponsor
- Bayer
Renal Failure
A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function
A study to evaluate the drug effect, safety, and tolerability of BMS-986259 in participants with different levels of kidney function
- Trial name
- NCT04237831
- Testing
- BMS-986259
- Where
- 3 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Polycystic Kidney, Autosomal Dominant
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
The purpose of the trial was to evaluate and describe the long term safety of tolvaptan in participants with autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT02251275
- Testing
- Tolvaptan
- Where
- 210 sites in United States, Argentina and 18 more
- Volunteers
- 1,803 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer Disease
Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function
The purpose of this study is to evaluate the pharmacokinetics properties of idalopirdine following multiple dosing in patients with renal impairment and compare to those in healthy subjects
- Trial name
- NCT02340195
- Testing
- Idalopirdine (Lu AE58054) 60 mg
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease
A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.
The purpose of this study is to evaluate the safety, tolerability and the pharmacodynamics (PD) of AZD4144 following oral administration in participants with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney…
- Trial name
- NCT06675175
- Testing
- AZD4144
- Where
- 15 sites in United States, Bulgaria and 2 more
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Pregnancy, GBS
Clinical Evaluation of the ARIES Group B Streptococcus (GBS) Assay
The ARIES GBS Assay is a real-time PCR based qualitative test designed to detect Group B Streptococcus (GBS) nucleic acid from Lim Broth enriched vaginal-rectal specimen swabs obtained from pregnant women between 35 - 37 weeks…
- Trial name
- NCT02497430
- Where
- 5 sites in United States
- Volunteers
- 918 people, healthy volunteers welcome
- Sponsor
- Luminex Corporation
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.
- Trial name
- AGLOW (NCT07161037)
- Testing
- VX-407
- Where
- 43 sites in United States, Belgium and 6 more
- Volunteers
- 26 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Chromosome 13 Aneuploidy, Chromosome 18 Aneuploidy
Non-invasive Prenatal Diagnostic Validation Study
The primary purpose of this study is to collect maternal blood samples from pregnant women to develop a non-invasive prenatal diagnostic test based on fetal DNA isolated from maternal blood.
- Conditions
- Chromosome 13 Aneuploidy, Chromosome 18 Aneuploidy, Chromosome 21 Aneuploidy, Sex Chromosome Aberrations
- Trial name
- NIPD (NCT01574781)
- Testing
- Blood draw, Cheek swab/Saliva Sampling
- Where
- United States
- Volunteers
- 1,781 people, healthy volunteers welcome
- Sponsor
- Natera, Inc.
Ovarian Neoplasms
Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass.
ANGLE has developed the Parsortix™ Cell Separation System (Parsortix), an automated system capable of harvesting rare circulating cells for analysis from a sample of peripheral blood based on cellular size and deformability.
- Trial name
- NCT02785731
- Testing
- Pelvic imaging, Blood draw, laparotomy or laparoscopy
- Where
- 5 sites in Austria, Germany
- Volunteers
- 204 people
- Sponsor
- Angle plc
Ovarian Cancer
A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer
This is an open label, multi-center, Phase 1/2 clinical trial in subjects with recurrent adenocarcinoma of the ovary who have been previously treated with a minimum of two courses of platinum-based chemotherapy, and up to two…
- Trial name
- REPROVe (NCT03281681)
- Testing
- VAL-083, Dianhydrogalactitol
- Where
- 3 sites in United States
- Sponsor
- DelMar Pharmaceuticals, Inc.
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of VX-407 in healthy participants.
- Trial name
- NCT07022119
- Testing
- VX-407
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program
The primary objective(s) of the study is to evaluate the impact of exposure to SC Peginterferon beta-1a or IM Interferon beta-1a before and during pregnancy on pregnancy outcome in female participants who had registered in the…
- Trial name
- NCT04655222
- Testing
- Interferon Beta Therapy
- Where
- Germany
- Volunteers
- 470 people
- Sponsor
- Biogen
Heavy Menstrual Bleeding, Abnormal Uterine Bleeding
A Registry to Gather Real World Use Data on the Cerene® Cryotherapy Device
Channel Medsystems, Inc., the manufacturer of the Cerene® Cryotherapy Device (Cerene), is initiating a prospective, observational registry, the Progress registry, to gather data during real world utilization of the Cerene®…
- Conditions
- Heavy Menstrual Bleeding, Abnormal Uterine Bleeding, Menorrhagia
- Trial name
- Progress (NCT05922657)
- Testing
- Cerene
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Channel Medsystems
X-linked Hypophosphatemia (XLH)
Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in adult Chinese patients with XLH
- Trial name
- NCT04842019
- Testing
- KRN23
- Where
- 5 sites in China
- Volunteers
- 18 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Urinary Bladder Overactive, Overactive Bladder
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
The purpose of this study was to examine how well the combination of two medicines (solifenacin succinate and mirabegron) worked compared to each medicine alone in the treatment of bladder problems, and how safe they were for…
- Conditions
- Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
- Trial name
- SYNERGY II (NCT02045862)
- Testing
- Solifenacin succinate, Mirabegron
- Where
- 251 sites in United States, Australia and 30 more
- Volunteers
- 1,829 people
- Sponsor
- Astellas Pharma Europe B.V.
Type 2 Diabetes Mellitus, Renal Impairment
Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment
The purpose of this study is to assess the safety and tolerability of dutogliptin in Type 2 diabetic subjects with moderate or severe renal impairment.
- Trial name
- NCT00958269
- Testing
- dutogliptin, sitagliptin
- Where
- 43 sites in United States, Russia and 1 more
- Volunteers
- 360 people
- Sponsor
- Phenomix
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.